Table 2.
Clinicopathological characteristics according to molecular L1CAM classification in early-stage endometrial cancer patients (n = 183).
| Characteristics | n = 183 |
POLEmut n = 29 |
MMR-D n = 53 |
p53abn n = 16 |
NSMP-L1CAM Neg n = 76 |
NSMP-L1CAM Pos n = 9 |
p-Value |
|---|---|---|---|---|---|---|---|
| Age | 0.038 | ||||||
| <60 | 134 | 22 (16.4%) | 43 (32.1%) | 8 (6.0%) | 57 (42.5%) | 4 (3.0%) | |
| ≥60 | 49 | 7 (14.3%) | 10 (20.4%) | 8 (16.3%) | 19 (38.8%) | 5 (10.2%) | |
| OP | 0.521 | ||||||
| Hysterectomy | 7 | 0 (0.0%) | 2 (28.6%) | 1 (14.3%) | 3 (42.9%) | 1 (14.3%) | |
| Hys+BSO | 19 | 1 (5.3%) | 4 (21.1%) | 2 (10.5%) | 10 (52.6%) | 2 (10.5%) | |
| Hys+BSO+LD | 157 | 28 (17.8%) | 47 (29.9%) | 13 (8.3%) | 63 (40.1%) | 6 (3.8%) | |
| Histologic type | <0.001 | ||||||
| Endometrioid | 166 | 29 (17.5%) | 51 (30.7%) | 4 (2.4%) | 75 (45.2%) | 7 (4.2%) | |
| Non-endometrioid | 17 | 0 (0.0%) | 2 (11.8%) | 12 (70.6%) | 1 (5.9%) | 2 (11.8%) | |
| Histologic grade | <0.001 | ||||||
| Low | 146 | 24 (16.4%) | 43 (29.5%) | 4 (2.7%) | 73 (50.0%) | 2 (1.4%) | |
| High | 37 | 5 (13.5%) | 10 (27.0%) | 12 (32.4%) | 3 (8.1%) | 7 (18.9%) | |
| LVSI | 0.329 | ||||||
| Absent | 152 | 26 (17.1%) | 40 (26.3%) | 15 (9.9%) | 64 (42.1%) | 7 (4.6%) | |
| Present | 31 | 3 (9.7%) | 13 (41.9%) | 1 (3.2%) | 12 (38.7%) | 2 (6.5%) | |
| Myometrial invasion | 0.324 | ||||||
| <50% | 145 | 24 (16.6%) | 40 (27.6%) | 14 (9.7%) | 62 (42.8%) | 5 (3.4%) | |
| >50% | 38 | 5 (13.2%) | 13 (34.2%) | 2 (5.3%) | 14 (36.8%) | 4 (10.5%) | |
| FIGO stage 2009 | 0.551 | ||||||
| IA | 133 | 23 (17.3%) | 36 (27.1%) | 14 (10.5%) | 56 (42.1%) | 4 (3.0%) | |
| IB | 33 | 5 (15.2%) | 11 (33.3%) | 0 (0.0%) | 13 (39.4%) | 4 (12.1%) | |
| II | 15 | 1 (6.7%) | 5 (33.3%) | 2 (13.3%) | 6 (40.0%) | 1 (6.7%) | |
| III | 2 | 0 (0.0%) | 1 (50.0%) | 0 (0.0%) | 1 (50.0%) | 0 (0.0%) | |
| FIGO stage updated 2023 | <0.001 | ||||||
| IA | 109 | 20 (18.3%) | 29 (26.6%) | 4 (3.7%) | 55 (50.5%) | 1 (0.9%) | |
| IB | 18 | 2 (11.1%) | 6 (33.3%) | 0 (0.0%) | 10 (55.6%) | 0 (0.0%) | |
| IC | 8 | 0 (0.0%) | 2 (25.0%) | 2 (25.0%) | 2 (25.0%) | 2 (25.0%) | |
| IIA | 9 | 1 (11.1%) | 2 (22.2%) | 0 (0.0%) | 6 (66.7%) | 0 (0.0%) | |
| IIB | 10 | 1 (10.0%) | 6 (60.0%) | 0 (0.0%) | 2 (20.0%) | 1 (10.0%) | |
| IIC | 29 | 5 (17.2%) | 8 (27.6%) | 10 (34.5%) | 1 (3.4%) | 5 (17.2%) | |
| Prognostic risk group * | <0.001 | ||||||
| Low | 100 | 20 (20.0%) | 28 (28.0%) | 3 (3.0%) | 48 (48.0%) | 1 (1.0%) | |
| Intermediate | 20 | 3 (15.0%) | 6 (30.0%) | 2 (10.0%) | 7 (35.0%) | 2 (10.0%) | |
| High intermediate | 47 | 6 (12.8%) | 17 (36.2%) | 1 (2.1%) | 20 (42.6%) | 3 (6.4%) | |
| High | 16 | 0 (0.0%) | 2 (12.5%) | 10 (62.5%) | 1 (6.3%) | 3 (18.8%) | |
| Adjuvant treatment | 0.019 | ||||||
| None | 147 | 25 (17.0%) | 41 (27.9%) | 12 (8.2%) | 64 (43.5%) | 5 (3.4%) | |
| Radiotherapy | 25 | 4 (16.0%) | 8 (32.0%) | 0 (0.0%) | 11 (14.3%) | 2 (8.0%) | |
| Chemotherapy | 7 | 0 (0.0%) | 2 (28.6%) | 3 (42.9%) | 1 (44.0%) | 1 (14.3%) | |
| Chemoradiotherapy | 4 | 0 (0.0%) | 2 (50.0%) | 1 (25.0%) | 0 (0.0%) | 1 (25.0%) |
BSO, bilateral salpingo-oophorectomy; LD, lymph node dissection; FIGO, International Federation of Gynecology and Obstetrics; LVSI, lymphovascular space invasion; MMR-D, mismatch repair-deficient; p53abn, p53-mutated; NSMP, no specific molecular profile; POLEmut, DNA polymerase epsilon-mutated; * risk stratified according to the 2016 ESMO/ESTRO/ESGO consensus guidelines.